SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that ...
Tempest Therapeutics, Inc. (TPST) has been able to make significant progress in advancing the use of its lead drug TPST-1120 for the treatment of patients with advanced solid tumors. In particular, it ...
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers Based on subsequent positive randomized data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results